Second, while CEACAM6 is well known to contribute to chemoresistance in pancreatic cancer [5,14,35], we did not evaluate the potential synergistic effects of combining gemcitabine with siCEACAM6-pHLIP or miR-29a-pHLIP, which warrants further investigation to enhance the clinical relevance of CEACAM6-targeted RNA therapies. This evidence concerns the gene CEACAM6 and pancreatic neoplasm.